AstraZeneca’s Q4 results were disappointing, both from a sales growth and profitability perspective. While Oncology and CVRM (to some extent) remain the key growth drivers, growing competition is concerning. Moreover, with the 2019-nCoV scare, near-term business visibility has hit a low. However, the group still has one of the largest oncology pipelines in our coverage and is awaiting/applying for/in major new indications/geographies in Oncology and even CVRM, which should give a push t ....